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Background: Carcinoembryonic antigen (CEA) is a protein commonly found in human serum, with elevated CEA
levels being linked to the progression of a wide range of tumors. It is currently used as a biomarker for malign
tumors such as lung cancer and colorectal cancer [Urol Oncol: Semin Orig Invest 352: 644–648, 2013 and Lung
Cancer 80: 45-49, 2013]. However, due to its low specificity in clinical applications, CEA can be used for monitoring
only, rather than tumor diagnosis. The function of many glycoproteins is critically dependent on their glycosylation
pattern, which in turn has the potential to serve in tumor detection. However, little is known about the detailed glycan
patterns of CEA.
Methods: To determine these patterns, we isolated and purified CEA proteins from human tumor tissues using
immunoaffinity chromatography. The glycan patterns of CEA were then analyzed using a Matrix-Assisted Laser
Desorption/Ionization-Time of Flight-Mass Spectrometry3 (MALDI-TOF-MS3) approach.
Results: We identified 61 glycoforms in tumor tissue, where CEA is upregulated. These glycosylation entities were
identified as bi-antennary, tri-antennary and tetra-antennary structures carrying sialic acid and fucose residues, and
include a multitude of glycans previously not reported for CEA.
Conclusion: Our findings should facilitate a more precise tumor prediction than currently possible, ultimately
resulting in improved tumor diagnosis and treatment.
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Human Carcinoembryonic Antigen (CEA) is a glycopro-
tein that is expressed during embryonal development
[1]. It was identified in human cancer tissues, and is
now known to be related to the progression of tumors
[2, 3]. As a tumor marker, CEA has been utilized in the
monitoring of tumor, judgment of neoplasm staging, as
well as prediction of tumor recurrence [4]. However,
further investigation revealed that detection of this antigen
alone is not sufficiently specific for tumor diagnostics.
Therefore, improvement in specificity of CEA detection
remains a challenge for clinical tumor diagnosis [5].
The proper functioning of glycoproteins is directly
related to the nature of their carbohydrate moiety changes
in protein, and dysregulation of glycosylation patterns
appears to play a crucial role in the pathogenesis and* Correspondence: yanli@ibp.ac.cn
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increase in fucosylation and formation of new glycan
antennae are characteristic features of carbohydrate chains
that appears to associate with the occurrence of related
diseases [6]. For example, core fucosylation (CF)-glycosyl-
ation of an α-fetoprotein isoform (AFP-L3) was approved
as a biomarker of hepatocellular carcinoma (HCC) by US
Food and Drug Administration (FDA) [7]. Similar to AFP-
L3, the use of CEA glycoprotein pattern has the potential
to improve the specificity of tumor diagnosis.
CEA contains 28 potential N-liked glycosylation sites,
and the glycofraction includes mannose, galactose,
N-acetylglucosamine, fucose and sialic acid [8]. The
glycan composition of CEA displays a considerable
heterogeneity in the sugar content of the antenna, but
detailed structures of these glycans have so far not been
reported [9]. One earlier study identified the core
structures of CEA oligosaccharides and proposed that
CEA contained approximate 40 N-linked oligosacchariderticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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carbohydrate structures of CEA were determined, and
complex-type and high mannose-type carbohydrate chains
were analyzed [9].
Various techniques are currently in use to analyze gly-
cans, including liquid chromatography (LC), lectin micro-
array, exoglycosidases digestion, capillary electrophoresis
(CE) and MALDI-TOF-MSn. Methods involving LC and
exoglycosidase digestion require large amounts of sample
material, and are therefore not suitable for clinical appli-
cation. In addition, specific glycan structures cannot be
obtained by lectin microarray analysis to investigate carbo-
hydrate moieties. Moreover, standard and purified glycans
are required for CE analysis. Except for MALDI-TOF-MSn,
all of the methods for structure analysis of CEA glycans
mentioned above are sample/standard-consuming as well
as cost-intensive. More importantly, specific glycan struc-
tures of CEA have not been entirely resolved. In contrast,
MALDI-TOF-MSn is both sensitive and can be used in
high through-put mode. Furthermore, uncertain fragments
of glycans can be further decomposed until specific and
detailed structures are obtained. As a result, components,
sequence and branches of glycans can be specifically ob-
tained by using MALDI-TOF-MSn. In order to investigate
glycan structures of humanized CEA, we first extracted
CEA from colon tumor using monoclonal anti-CEA
coupled to activated Sepharose 4B. Glycan structures of ex-
tracted CEA were then analyzed using MALDI-TOF-MS3,
which allowed for sensitive identification of a multitude of
previously unknown glycan structures.
Methods
Materials
Trihydroxymethylaminomethane, sodium chloride, so-
diumdeoxycholate, sodium dodecyl sulfate, disodium
hydrogen phosphate, sodium phosphate monobasic so-
dium carbonate, hydrochloric acid, ammonium bicar-
bonate, sodium hydroxide, standard peptides, glycine,
ethanolamine, propanol, DL-dithiothreitol (DTT), iodoa-
cetamide (IAA), cyanogens bromide, acetic acid and
phosphate buffer were purchased from Sigma-Aldrich.
Acetonitrile, ethanol and water were of analytical grade
and obtained from Avantor Performance Materials, Inc.
(PA, USA). Mouse anti-CEA antibody was purchased
from ZSG-BIO (Beijing, China). Trypsin and peptide N-
glycosidase F (PNGase F) were purchased from Promega
Corporation (WI, USA). C18-Sep-Pak cartridges were
obtained from Waters Corporation (MA, USA). Clinical
samples of rectum loops from patients with colorectal
carcinoma were provided by Beijing Cancer Hospital.
CEA extraction and purification
Colorectal carcinoma tissue was placed on ice, and blood
was washed off using 0.01 M PBS buffer. Adiposetissuewas cut into pieces and RIPA lysis buffer (0.15 g Tris,
0.438 g NaCl, 0.05 g NaOH, 0.5 g sodiumdeoxycholate,
and 0.05 g SDS) was added to the tissue pieces. The
mixture was grinded into homogenate in a tissue grinder.
All the tissue homogenate was ultrasonically decomposed
thoroughly in the lysis buffer. Then the tissue homogenate
was centrifuged at 4000 g, and the supernatant was kept
on ice, at −80 °C.
Sepharose 4B stored in 20 % ethanol was applied onto
a cartridge, and activated with cyanogens bromide solu-
tion in the presence of 2 M Na2CO3. Mouse anti-CEA
was mixed and conjugated with the activated gel on the
cartridge overnight at 4 °C. Remaining activated groups
were blocked with 0.2 M ethanolamine (pH 7 ~ 8), and
any excess of uncoupled proteins were washed off by
PBS buffer (pH = 7.4) for three times. 0.5 mL of super-
natant of the homogenate was fractionated overnight at
4 °C using an anti-CEA immunoadsorbent cartridge.
Target CEA was eluted from the cartridge using 0.1 M
glycine-HCl (pH 2.4) after washing with PBS buffer three
times. The purity of eluted CEA was confirmed using
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE, see Fig. 1b). Afterwards, the concentration
of eluted CEA was determined using an enzyme-linked
immunoadsorbent assay (ELISA).
N-glycan release
Purified CEA was first reduced and carboxymethylated
in the presence of DTT and IAA followed by dialysis in
50 mM Ambic buffer for 24–48 h at 4 °C. Glycoproteins
were further incubated at 37 °C overnight to be cleaved
into glycopeptides by tryptic digestion. First, the Sep-Pak®
C18 cartridge was conditioned with methanol, 5 % acetic
acid and the 100 % propan-1-ol, and then glycopeptide
samples were applied to the cartridge. Second, samples
were eluted stepwise with 20 % propan-1-ol solution
and 40 % propan-1-ol solution. Third, the propanol
Sep-Pak fractions were digested at 37 °C for 20–24 h
using PNGase F. Separation of the N-glycans from the
mixtures was conducted using a Sep-Pak® C18 propanol/
5 % acetic acid system. Finally, permethylation and
subsequent purification were performed according to
previously described [11].
Structure analysis of N-linked glycans released from
extracted CEA
Fractions of N-linked glycan mixtures from extracted
CEA were analyzed using an Axima MALDI Resonance
mass spectrometer (Shimadzu). A nitrogen laser was
used to irradiate samples at 337 nm, and an average of
200 shots was taken. An aqueous solution of N-linked
oligosaccharide mixture (ca. 100 pmol, 0.5 μL) was applied
to a μfocus MALDI plate target (900 μm, 384 circles, HST
Inc.). A solution (0.5 μL) of 2,5-dihydroxybenzoic acid
A B
Fig. 1 Scheme of CEA extraction and purification (a), and SDS-PAGE analysis of CEA and molecular weight markers (b). Lanes of MW, a and b
represent molecular weight markers, CEA standard and extracted CEA from colorectal carcinoma patients respectively



















Fig. 2 Calibration curve of standard CEA using ELISA
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containing 0.1 % trifluoroacetic acid (TFA) and 1 mM Na+
were added to the plate, and then mixed with oligosaccha-
rides. Finally, the mixture was exposed to air at room
temperature until dry. During MS, the ion peaks were




In order to analyze the glycan moieties of CEA, we first
isolated and purified CEA protein by immunoadsorption
from human tumor tissues. CEA antibodies were first
covalently coupled to Sepharose beads, to then allow
target CEA to be precipitated, before it was eluted from
the cartridge (Fig. 1a). Non-specific binding, resulting in
low signal-to-noise-ratio, was avoided through covalent
coupling of CEA antibodies. The concentration of eluted
CEA was determined using an ELISA method. Using a
standard curve (Fig. 2), we estimated that our procedure
yielded approximate 12 ng CEA glycoproteins per
400 mg of colorectal carcinoma tissue used.
Analysis of N-linked glycan structures of extracted CEA
To investigate the specific glycan structures present in
CEA, we analyzed our samples using MALDI-TOF-MS3.We detected the presence of 61 unique glycans in the
extracted CEA. These glycans were detected without
further separation, and were found to be all linked to
asparagine (see Fig. 3 and Additional file 1: Table S1). In
addition, the proposed N-glycan assignments for all
peaks are shown. First, we analyzed the terminal struc-
tures of glycans of CEA. Furthermore, MS/MS/MS
analysis of the assigned glycans was performed (see
Additional file 2: Figures S1-S61). The spectra showed






Fig. 3 (See legend on next page.)
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Fig. 3 MALDI-TOF MS profiles of the permethylated N-linked glycans from CEA of colorectal carcinoma patients. All molecular ions are present in
singly charged sodiated form ([M + Na]+). In the glycan structure, blue square refers to N-acetylglucosamine (■), green circle refers to mannose
(●), yellow circle refers to Galactose (●), red triangle refers to Fucose (▲), and purple diamond refers to N –acetylneuraminic acid (♦). a-e refers to
mass spectrum of CEA glycans in different mass range
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ture, 14 were of a tri-antennary structure, and 17 were
of tetra-antennary structure. Interestingly, one glycan
with hybrid structure was determined as well.
As expected, more than half of the 61 N-linked gly-
cans contained one or two residues of sialic acid at-
tached to the terminal galactosyl group. Intriguingly,
more than half of these glycans contained as many as
two residues of fucose. These fucose molecules were linked
either to a reducing terminal N-acetylglucosaminide, or a
non-reducing end of the glycans. In addition, 23 N-linked
glycans were found to contain both sialic acid and fucose
residues. Interestingly, 23 N-linked glycans contained a
SialylLewisx terminal structure, thus accounting for
approximate 38 % of all glycan moieties determined.
The presence and determined level of SialylLewisx
structure are in agreement with those reported in earlier
studies, where SialylLewisx was identified as a cancer
marker [12].
Second, we investigated the core structures of the
CEA glycan moeties. 31 CEA glycans (approximate
50 %) contained core fucosylation. During core fucosyla-
tion, fucose is transferred from guanosinediphosphate-
fucose (GDP-Fuc) to the innermost GlcNAc catalyzed by
core fucosyltransferase [7]. Similar to SialylLewisx, these
results are in agreement with the literature describing
core fucosylation as a cancer marker [13, 14]. In conclu-
sion, our method is sensitive, and can be used for glycan
detection of clinical samples. Our analysis indicated that
tumor CEA proteins contain high levels of glycan struc-
tures such as SialylLewisx and core fucosylation, which
have previously been associated with tumor tissue.
Discussion and conclusions
We identified 61 different glycosylated forms of CEA in
the tumor samples analyzed. These structures included
bi-antennary, tri-antennary and tetra-antennary struc-
tures carrying sialic acid and fucose residues. In addition,
we showed that the presence of SialylLewisx and core
fucosylation structures could facilitate the specificity
improvement of CEA for cancer detection.
Glycan structures
Glycans possess several important features, including the
ability of different types and numbers of sugar residues
to form glycosidic bonds with one another, the type of
anomeric linkage, the position and the absence or pres-
ence of branching. Together, these characteristics giverise to the complex heterogeneity in living systems. If
some of these characteristics change, transformation of
cells or tissues may occur. Therefore, glycan structure
analysis should greatly improve the specificity and
sensitivity of potential biomarkers that at present are not
sufficiently specific for clinical tumor diagnosis. Cur-
rently, detection of CEA is not specific enough for
adequate diagnosis of colonic neoplasia, and therefore
CEA levels are only monitored as a prognostic indicator
therapy response. Investigation of CEA glycans struc-
tures such as SialylLewisx units and fucosylation levels
will greatly contribute to a more specific diagnosis of
colorectal carcinoma.
The determined SialylLewisx structure here is in agree-
ment with previous studies that reported the presence of
SialylLewisx in malignancies [15–22]. SialylLewisx is an
adhesion molecule present on O-and N-linked oligosac-
charides, and is therefore of great significance in cell-cell
recognition [23]. Importantly, SialylLewisx is thought to
be associated with metastatic ability of tumor cells, and
has the potential to be used as a marker for pathological
tumor extensiveness, e.g., nodal extension or distant
metastasis [24]. It was reported earlier that SialylLewisx
is a tumor-specific glycan marker used for tumor
staging, prognosis and progression, and was found to be
associated with proteins such as alpha 1-acid glycopro-
tein, CD66, and MUC7 [25–28]. It has also been demon-
strated that SialylLewisx is present at elevated levels in
primary breast carcinoma [29]. Fucosylation levels in-
creased significantly when malignant transformation
occurred in the tissue cells. It has been proved that
core-fucosylation is involved in the regulation of many
biological processes in mammals. Abnormal core-
fucosylation was previously reported to be involved in
human pathological processes, such as metastasis [7].
However, few reports exist that tested the use of Sialyl-
Lewisx and core-fucosylation as tumor markers for
colorectal carcinoma. Based on our results here, the
SialylLewisx and core-fucosylation structures do present
in CEA protein extracted from colon carcinomas tissues.
The results of our present study indicate that deter-
mined levels of SialylLewisx and core fucosylation of
CEA proteins could be useful and specific indicators for
colorectal carcinoma.
CEA samples from human
CEA samples from human rather than recombinant pro-
teins are essentially required to improve the diagnostic
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cation. Biological synthesis of glycan chains is a non-
template and complicated process, and this metabolic
pathway cannot be controlled as accurately as nucleic
acid and proteins. Moreover, synthesis and rupture of
glycosidic bonds are controlled by either glycosyltrans-
ferase or hydrolase in endoplasmic reticulum and Golgi
apparatus, and these processes are extraordinarily non-
deterministic. Glycan structures in recombinant proteins
may be different from glycan structures synthesized via
the mentioned process in the endoplasmic reticulum
and Golgi apparatus of glycoproteins extracted from
human patients. Consequently, CEA samples from
human patients are necessary for studies about clinical
application. In the present study, CEA samples were
extracted and purified from patients, thus the harvested
glycan structures represent exactly those synthesized in
biological systems. Therefore, the determined glycan
structures should assist greatly in improving the specifi-
city of cancer diagnosis in clinical application.
Analysis method
CEA concentrations in human samples are in the level
of ng/mL, and it is therefore necessary to use highly
sensitive detection methods for the analysis of its glyco-
sylation patterns. MALDI-TOF-MS method possesses a
much higher sensitivity compared to those reported pre-
viously for CEA glycan analysis. In a previous study that
used limited exoglycosidase digestion and methylation
analysis, the amount of CEA proteins required was
almost 10 mg for glycan analysis [8]. In the present
study, only 5 μg of CEA proteins were required for one
spot on the MALDI plate, indicating that our method is
sensitive, with the amount of material required being
three magnitudes lower. In addition, permethylation of
released glycans were optimized in this study, and the
experiment time was shortened without effect on results.
All the structures of N-linked glycans were obtained and
analyzed using MALDI-TOF-MS3 in about 60 min after
glycans were released from CEA proteins. The proced-
ure of glycans release in this study was mainly composed
of tryptic digestion, N-Glycosidase F digestion and the
necessary clean-up of products by Sep-Pak purification
steps respectively. However, the reported routine proce-
dures of glycans release and structure analysis of glycan
moieties of CEA proteins often include multistep en-
zyme digestion, liberation of glycans and complicated
methylation analysis [9, 10]. Therefore, short analysis
time and simple treatment process contributed to high
through-put of current methods, especially when mul-
tiple clinical samples were required to be analyzed
rapidly. The limitation of our method presented here is
that linkage information of glycans could not be
obtained, apart from branch and sequence information.Nevertheless, we believe that information about compos-
ition, branch architecture and sequences of the CEA gly-
can moieties should be sufficient to improve the specificity
of CEA to allow its use as a colon tumor marker.
Conclusions
A method including extraction, purification of glycopro-
tein CEA from tumor tissue, and characterization of
CEA glycans structures was developed. Sixty-one unique
oligosaccharides were obtained, and structures of these
glycans were investigated. The presented methodology
should greatly assist further study of CEA proteins and
its application as a specific colon tumor marker, and
glycans signatures may become useful markers for the
distinction of cancers.
Additional files
Additional file 1: Table S1. N-glycans harvested from CEA of colorectal
carcinoma patients.
Additional file 2: Supporting Information (Figures S1-S61).
Abbreviations
CEA: Carcinoembryonic antigen; MALDI-TOF-MSn: Matrix-Assisted Laser
Desorption/Ionization-Time of Flight-Mass Spectrometryn; CF: Core
fucosylation; HCC: Hepatocellular carcinoma; FDA: US Food and Drug
Administration; LC: Liquid chromatography; CE: Capillary electrophoresis;
DTT: DL-Dithiothreitol; IAA: Iodoacetamide; PNGase F: Peptide N-glycosidase
F; ELISA: Enzyme-linked immunoadsorbent assay; DHB: 2,5-Dihydroxybenzoic
acid; TFA: Ttrifluoroacetic acid; GDP-Fuc: Guanosinediphosphate-fucose; MS/
MS/MS: Tandem mass spectrometry; m/z: Mass to charge ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CH carried out the glycan pattern studies, MALDI-TOF-MS experiments,
glycan structure analyses and participated in drafting the manuscript. TZ
contributed to the isolation and purification of colorectal carcinoma tissue,
and provided extensive discussion and clinical information. YL contributed to
ELISA experiments and quantification of purified CEA. QL and HW performed
N-glycan release and purification, and SDS-PAGE experiments. DJ collected
samples from patients, and provided clinical information. YL conceived the
study, contributed to its design and coordination, participated in drafting the
manuscript and critical review. All authors read and approved the final
manuscript.
Acknowledgments
This work was supported by the National Natural Science Foundation of China
(No. 31270909), Major Projects for Infectious Diseases of Ministry of Health (No.
2013ZX10004216-002), Project for Scientific Equipment Development of Chinese
Academy of Sciences (No. YZ201249). We are also indebted to the STS Project
of Chinese Academy of Sciences (No. Y4CQ041) and Project for Key Technology
Development of Metabolomic Quantitative Analysis (No. Y486041). Help from
Torsten Juelich in Peking University for assistance with discussion and editing is
greatly acknowledged.
Author details
1Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,
P. R. China. 2Key laboratory of Carcinogenesis and Translational Research
(Ministry of Education), Department of Colorectal Surgery, Peking University
Cancer Hospital & Institute, No. 52 Fucheng Rd., Haidian District, Beijing
100142, P. R. China.
Huang et al. Clinical Proteomics  (2015) 12:17 Page 7 of 7Received: 27 March 2015 Accepted: 12 June 2015
References
1. Kim B-J, Baek S, Lee SH, Ahn SH, Kim H-M, Kim HS, et al. Higher serum
carcinoembryonic antigen levels associate with more frequent development
of incident fractures in Korean women: a longitudinal study using the
national health insurance claim data. Bone. 2015;73:190–7.
2. Loeser A, Neumann M, Kocot A, Vergho DC, Spahn M, Riedmiller H. Serum
carcino-embryonic antigen (CEA) and its possible use as tumor marker for
secondary tumors in urinary intestinal reservoirs. Urol Oncol. 2013;31:644–8.
3. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y.
Diagnostic value of CEA and CYFRA 21–1 tumor makers in primary lung
cancer. Lung Cancer. 2013;80:45–9.
4. Lee W-S, Baek J-H, Kim K-K, Park YH. The prognostic significant of percentage
drop in serum resection for colon cancer. Surg Oncol. 2012;21:45–51.
5. Lee W-S, Baek J-H, Kim KK, Park YH. The prognostic significant of percentage
in serum CEA post curative resection for colon cancer. Lung Cancer.
2012;76:138–43.
6. Aoyagi Y, Suzuki Y, Igarashi K, Saitoh A, Oguro M, Yokota T, et al.
Carbohydrate structures of human alpha-fetoprotein of patients with
hepatocellular carcinoma: presence of fucosylated and non-
fucosylatedtriantennaryglycans. Br J Cancer. 1993;67:486–92.
7. Ma C, Zhang Q, Qu J, Zhao X, Li X, Liu Y, et al. A precise approach in
large scale core-fucosylated glycoprotein identification with low- and
high-normalized collision energy. J Proteomics. 2015;114:61–70.
8. Thmpson JA. Molecular cloning and expression of carcinoembryonic
antigen gene family members. Tumour Biol. 1995;16:10–6.
9. Yamashita K, Totani K, Kuroki M, Matsuoka Y, Ueda I, Kobata A. Structure
studies of the carbohydrate moieties of carcinoembryonic antigens. Cancer
Res. 1987;47:3451–9.
10. Chandrasekaran EV, Davila M, Nixon DW, Goldfarb M, Mendicino J. Isolation
and structures of the oligosaccharide units of carcinoembryonic antigen.
J Biol Chem. 1983;258:7213–22.
11. Canis K, Mxkinnon TA, Nowak A, Haslam SM, Panico M, Morris HR, et al.
Mapping the N-glycome of human von willebrand factor. Biochem J.
2012;447:217–28.
12. Rho J-H, Mead JR, Wright WS, Brenner DE, Stave JW, Gildersleeve JC, et al.
Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers
using high density antibody arrays. J Proteomics. 2014;96:291–9.
13. Aoyagi Y, Mita Y, Suda T, Kawai K, Kuroiwa T, Igarashi M, et al. The fucosylation
index of serum alpha-fetoprotein as useful prognostic factor in patients with
hepatocellular carcinoma in special reference to chronological changes.
Hepatol Res. 2002;23:287.
14. Igarashi Y, Aoyagi T, Suda Y, Mita K. Kawai, Studies on the correlation
among the fucosylation index, concentration of alpha-fetoprotein and
des-gamma-carboxy prothrombin as prognostic indicators in hepatocellular
carcinoma. Hepatol Res. 2003;27:280–8.
15. Gorelik E, Galili U, Raz A. On the role of cell surface carbohydrates and their
binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev.
2001;20:245–77.
16. Sharon N, Lis H. History of lectins: from hemagglutinins to biological
recognition molecules. Glycobiology. 2004;14:53R–62.
17. Danussi C, Coslovi A, Campa C, Mucignat MT, Spessotto P, Uggeri F, et al.
A newly generated functional antibody identifies Tn antigen as a novel
determinant in the cancer cell-lymphatic endothelium interaction.
Glycobiology. 2009;19:1056–67.
18. Goetz JA, Mechref Y, Kang P, Jeng MH, Novotny MV. Glycomic profiling of
invasive and non-invasive breast cancer cells. Glycoconj J. 2009;26:117–31.
19. Patsos G, Hebbe-Viton V, Robbe-Masselot C, Masselot D, Martin RS,
Greenwood R, et al. O-Glycan inhibitors generate aryl-glycans, induce
apoptosis and lead to growth inhibition in colorectal cancer cell lines.
Glycobiology. 2009;19:382–98.
20. Powlesland AS, Hitchen PG, Parry S, Graham SA, Barrio MM, Elola MT, et al.
Targeted glycoproteomic identification of cancer cell glycosylation.
Glycobiology. 2009;19:899–909.
21. Rek A, Krenn E, Kungl AJ. Therapeutically targeting protein–glycan
interactions. Br J Pharmacol. 2009;157:686–94.
22. Renkonen J, Paavonen T, Renkonen R. Endothelial and epithelial expression of
sialylLewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer.
1997;74:296–300.23. Iwata T, Nishiyama N, Nagano K, Izumi N, Tsukioka T, Chung K, et al.
Preoperative serum value of sialyl Lewis X predicts pathological noda l
extens ion and survival in patients with surgically trea ted small cell lung
cancer. J Surg Oncol. 2012;105:818–24.
24. Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, et al. α2,3-
Sialyltrans -ferase ST3Gal IV promotes migration and metastasis in pancreatic
adenocarcinoma cells and tends to be highly expressed in pancreatic
adenocarcinoma tissues. Int J Biochem Cell Biol. 2013;45:1748–57.
25. Remmers N, Anderson JM, Linde EM, Dimaio DJ, Lazenby AJ, Wandall HH,
et al. Aberr ant expression of mucin core proteins and o-link ed glycans
associated with progression of pancreatic cancer. Clin Cancer Res.
2013;19:1981–93.
26. Croce MV, Salice VC, Lacunza E, Segal-Eira SA. Alpha 1-acid glycoprotein
(AGP): a possible carrier of sialyllewis X (slewis X) antigen in colorectal
carcinoma. Histol Histopathol. 2005;20:91–7.
27. Stocks SC, Kerr MA. Neutrophil NCA-160 (CD66) is the major protein carrier
of selec tin binding carbohydrate groups LewisX and sialylLewisX. Biochem
Biophys Res Commun. 1993;195:478–83.
28. Karlsson NG, Thomsson KA. Salivary MUC7 is a major carrier of blood group
I type O-linked oligosaccha rides serving as the scaffold for sialyl Lewis X.
Glycobiology. 2009;19:288–300.
29. Shida K, Misonou Y, Korekane H, Seki Y, Noura S, Ohue M, et al. Unusual
accumulation of sulfated glycosphingolipids in colon cancer cells.
Glycobiology. 2009;19:1018–33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
